In a prespecified secondary analysis of the phase 3 SELECT trial, once-weekly semaglutide 2.4 mg reduced high-sensitivity C-reactive protein by 37.8% versus placebo at 104 weeks among adults with...
In a retrospective, propensity score-matched national cohort of adults with type 2 diabetes mellitus undergoing primary total knee arthroplasty, semaglutide and tirzepatide were associated with similar...
At the 2026 American Academy of Neurology Annual Meeting in Chicago, IL, investigators presented real-world evidence evaluating whether glucagon-like peptide-1 receptor agonists influence healthcare...
An integrated UK Biobank and preclinical study linked obesity-related metabolic inflammation to PTPN11-mutant myeloid leukemia and found that combined GLP-1R agonism and IL-17A blockade reduced leukemic...
In the phase 3a REIMAGINE 1 trial, once-weekly cagrilintide–semaglutide reduced HbA1c vs placebo at 40 weeks in adults with early-stage type 2 diabetes that was inadequately controlled with diet and...
In a post hoc analysis of the SURPASS-CVOT randomized clinical trial, researchers found that tirzepatide was associated with fewer cardiorenal events than dulaglutide in high-risk type 2 diabetes.
